Skip to main content
Premium Trial:

Request an Annual Quote

Lynx CEO Resigns As Company Proceeds With Solexa Merger

NEW YORK, Nov. 22 (GenomeWeb News) - Kevin Corcoran has resigned as CEO, president, and director of Lynx Therapeutics "to pursue another business opportunity," Lynx said last week.


He will be replaced by Mary Schramke, Lynx's vice president of product development, who will become acting CEO on Dec. 15. She will lead the company as it proceeds with its merger with Solexa. Schramke holds a PhD in microbiology from LouisianaStateUniversity, Baton Rouge, and an MBA from JohnF.KennedyUniversity.


Corcoran spent nine years at Lynx, working in various managerial positions, and was responsible for the company's short read DNA sequencing technology.

Lynx and Solexa are scheduled to merge during the first quarter of 2005. The companies had originally planned to tie the knot during the fourth quarer of 2004.

Read the following most-recent GenomeWeb News articles about Lynx and its impending merger with Solexa:


Lynx Reports Lower Q3 Revenues Amid Flat Expenses; Stock Rises and Falls  (11/15/04)

Lynx, In Worse Shape Than Previously Thought, Gets More Cash From Solexa (10/29/04)